Formalin-fixed, paraffin-embedded human Histiocytoma stained with HLA-DR Monoclonal Antibody (SPM423).
Western Blot Analysis of human Spleen tissue lysate using HLA-DR Monoclonal Antibody (SPM423).
Immunofluorescence Analysis of Raji cells labeling HLA-DR with HLA-DR Monoclonal Antibody (SPM423) conjugated with CF594 (Green). The nuclear counterstain is Reddot (Red)
Flow Cytometric Analysis of human Raji cells using HLA-DR MAb (SPM423) followed by Goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).
Known Applications & Suggested Dilutions
Host / Ig Isotype
Mol. Weight of Antigen
Specificity & Comments
This MAb reacts with a 28kDa chain of HLA-DRB1 antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. The L243 antibody recognizes a different epitope than the LN3 monoclonal antibody, and these antibodies do not cross-block binding to each other's respective epitopes. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha (heavy) chain and a 28kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.